PCSK9 inhibition has emerged as an effective, approved and marketed LDL-C-lowering therapy where monoclonal antibodies (mAbs) to PCSK9 profoundly reduce LDL-C in FH patients [78–82]{Sahebkar, 2013 #48; Sahebkar, 2013 #49}. Here, PCSK9 is linked to familial hyperaldosteronism.